淋巴细胞白血病-话题@MedSci

#淋巴细胞白血病#

277篇内容 | 4603人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2194514, encodeId=53b12194514bd, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a> <a href='/topic/show?id=bde45355068' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞白血病#</a>, objectTitle=淋巴细胞白血病全方位解析|从指南到实践，为医生提供全方位支持, objectType=article, longId=817668, objectId=2daf81e668ca, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240321/1711014061804_8538692.png, objectUrl=/article/show_article.do?id=2daf81e668ca, replyNumber=0, likeNumber=71, createdTime=2024-03-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=2daf81e668ca, moduleTitle=淋巴细胞白血病全方位解析|从指南到实践，为医生提供全方位支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2daf81e668ca)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2175616, encodeId=a4a921e561667, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=WHO 淋巴母细胞白血病/淋巴瘤分型 2016 版, objectType=article, longId=805675, objectId=cacc8056e532, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668019046680_4754896.png, objectUrl=/article/show_article.do?id=cacc8056e532, replyNumber=0, likeNumber=66, createdTime=2023-12-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=cacc8056e532, moduleTitle=WHO 淋巴母细胞白血病/淋巴瘤分型 2016 版, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cacc8056e532)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1998055, encodeId=dc0519980554e, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=J Clin Oncol：白消安 vs 全身放疗联合环磷酰胺治疗成人急性B淋巴细胞白血病, objectType=article, longId=739393, objectId=dc53e393931b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc53e393931b, replyNumber=0, likeNumber=178, createdTime=2023-04-10, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc53e393931b, moduleTitle=J Clin Oncol：白消安 vs 全身放疗联合环磷酰胺治疗成人急性B淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc53e393931b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998052, encodeId=8164199805270, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=Clin Cancer Res：维奈托克治疗前依鲁替尼导入治疗可有效改善慢性淋巴细胞白血病患者预后, objectType=article, longId=737802, objectId=9316e3780270, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9316e3780270, replyNumber=0, likeNumber=0, createdTime=2023-03-23, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9316e3780270, moduleTitle=Clin Cancer Res：维奈托克治疗前依鲁替尼导入治疗可有效改善慢性淋巴细胞白血病患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9316e3780270)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998050, encodeId=0cab1998050ff, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=BCR-ABL1融合基因阳性急性淋巴细胞白血病的那些小秘密, objectType=article, longId=732594, objectId=9881e3259437, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9881e3259437, replyNumber=0, likeNumber=87, createdTime=2022-08-28, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9881e3259437, moduleTitle=BCR-ABL1融合基因阳性急性淋巴细胞白血病的那些小秘密, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9881e3259437)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998039, encodeId=bdcf1998039ba, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=IJHS：美国急性淋巴细胞白血病的严重程度和死亡率住院：一项基于人群的研究, objectType=article, longId=727802, objectId=bf85e2780258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf85e2780258, replyNumber=0, likeNumber=90, createdTime=2023-04-26, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf85e2780258, moduleTitle=IJHS：美国急性淋巴细胞白血病的严重程度和死亡率住院：一项基于人群的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf85e2780258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998054, encodeId=456e1998054d2, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=Leuk Lymphoma：加拿大婴儿急性淋巴细胞白血病 (ALL)、亚二倍体 ALL 和混合表型急性白血病 (MPAL) 的预后因素和结局：来自 CYP-C 的报告, objectType=article, longId=738708, objectId=77ffe3870846, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77ffe3870846, replyNumber=0, likeNumber=103, createdTime=2023-04-08, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77ffe3870846, moduleTitle=Leuk Lymphoma：加拿大婴儿急性淋巴细胞白血病 (ALL)、亚二倍体 ALL 和混合表型急性白血病 (MPAL) 的预后因素和结局：来自 CYP-C 的报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77ffe3870846)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998045, encodeId=7f48199804573, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=ASCO 2022 | 慢性淋巴细胞白血病一线疗法：Calquence联合奥妥珠单抗持续生存获益：5年生存率达到90%！, objectType=article, longId=728833, objectId=026ae2883362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=026ae2883362, replyNumber=0, likeNumber=136, createdTime=2022-09-15, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=026ae2883362, moduleTitle=ASCO 2022 | 慢性淋巴细胞白血病一线疗法：Calquence联合奥妥珠单抗持续生存获益：5年生存率达到90%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=026ae2883362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998041, encodeId=1090199804178, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=Hematol Oncol：血清可溶性 CD23 水平是慢性淋巴细胞白血病首次治疗时间的独立预测因子, objectType=article, longId=727960, objectId=4d1fe27960c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d1fe27960c3, replyNumber=0, likeNumber=0, createdTime=2023-02-22, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d1fe27960c3, moduleTitle=Hematol Oncol：血清可溶性 CD23 水平是慢性淋巴细胞白血病首次治疗时间的独立预测因子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d1fe27960c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998051, encodeId=4a281998051b4, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=Leukemia：纪春岩教授团队揭示急性T淋巴细胞白血病治疗新靶点, objectType=article, longId=736546, objectId=4cc6e365468f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cc6e365468f, replyNumber=0, likeNumber=90, createdTime=2023-08-02, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cc6e365468f, moduleTitle=Leukemia：纪春岩教授团队揭示急性T淋巴细胞白血病治疗新靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cc6e365468f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998038, encodeId=40d0199803839, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=药明巨诺宣布倍诺达®针对儿童及年轻成人复发或难治性B细胞急性淋巴细胞白血病的临床试验申请获批, objectType=article, longId=724745, objectId=639fe24745ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=639fe24745ff, replyNumber=0, likeNumber=73, createdTime=2022-08-22, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=639fe24745ff, moduleTitle=药明巨诺宣布倍诺达®针对儿童及年轻成人复发或难治性B细胞急性淋巴细胞白血病的临床试验申请获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=639fe24745ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998046, encodeId=7d091998046ea, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=【即将直播】竺晓凡教授：儿童急性淋巴细胞白血病的诊治与并发症处理原则, objectType=article, longId=730353, objectId=76d9e3035375, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76d9e3035375, replyNumber=0, likeNumber=81, createdTime=2023-02-22, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76d9e3035375, moduleTitle=【即将直播】竺晓凡教授：儿童急性淋巴细胞白血病的诊治与并发症处理原则, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76d9e3035375)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998053, encodeId=2eab1998053f0, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=Lancet Haematol：Tisagenlecleucel在急性淋巴细胞白血病幼儿和婴儿患者中的临床真实数据, objectType=article, longId=738557, objectId=cac4e385573d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cac4e385573d, replyNumber=0, likeNumber=88, createdTime=2023-08-19, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cac4e385573d, moduleTitle=Lancet Haematol：Tisagenlecleucel在急性淋巴细胞白血病幼儿和婴儿患者中的临床真实数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cac4e385573d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998040, encodeId=15371998040e9, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=一例颗粒性-急性T淋巴细胞白血病案例分享, objectType=article, longId=727764, objectId=2bbce27764e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bbce27764e6, replyNumber=0, likeNumber=107, createdTime=2022-06-19, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bbce27764e6, moduleTitle=一例颗粒性-急性T淋巴细胞白血病案例分享, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bbce27764e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998049, encodeId=d2b119980496f, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=最强讲解|慢性淋巴细胞白血病诊断与鉴别诊断, objectType=article, longId=732127, objectId=57d3e32127d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57d3e32127d5, replyNumber=0, likeNumber=105, createdTime=2023-03-16, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57d3e32127d5, moduleTitle=最强讲解|慢性淋巴细胞白血病诊断与鉴别诊断, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57d3e32127d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998026, encodeId=592519980265e, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=HAEMATOLOGICA：伊布替尼治疗不能诱导慢性淋巴细胞白血病的TP53克隆进化, objectType=article, longId=218715, objectId=800e218e15c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=800e218e15c8, replyNumber=0, likeNumber=100, createdTime=2022-03-13, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=800e218e15c8, moduleTitle=HAEMATOLOGICA：伊布替尼治疗不能诱导慢性淋巴细胞白血病的TP53克隆进化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=800e218e15c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998028, encodeId=c36d199802893, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=Int J Epidemiol：常见的遗传多态性会增加慢性淋巴细胞白血病和非黑色素瘤皮肤癌之间的联系, objectType=article, longId=218829, objectId=acda21882903, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acda21882903, replyNumber=0, likeNumber=109, createdTime=2022-07-27, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acda21882903, moduleTitle=Int J Epidemiol：常见的遗传多态性会增加慢性淋巴细胞白血病和非黑色素瘤皮肤癌之间的联系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acda21882903)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998022, encodeId=77141998022c3, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=HAEMATOLOGICA：接受阿卡拉布替尼单药治疗的慢性淋巴细胞白血病患者的心血管不良事件: 762例患者的汇总分析。, objectType=article, longId=218053, objectId=6f90218053de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f90218053de, replyNumber=0, likeNumber=86, createdTime=2022-05-16, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f90218053de, moduleTitle=HAEMATOLOGICA：接受阿卡拉布替尼单药治疗的慢性淋巴细胞白血病患者的心血管不良事件: 762例患者的汇总分析。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f90218053de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998047, encodeId=97ad199804e18, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=NEJM Evid：固定疗程的伊布替尼联合维奈克拉（Ibr+Ven）一线治疗慢性淋巴细胞白血病结果公布（GLOW研究）, objectType=article, longId=731593, objectId=2592e3159385, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2592e3159385, replyNumber=0, likeNumber=102, createdTime=2023-02-17, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2592e3159385, moduleTitle=NEJM Evid：固定疗程的伊布替尼联合维奈克拉（Ibr+Ven）一线治疗慢性淋巴细胞白血病结果公布（GLOW研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2592e3159385)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998044, encodeId=6e4c199804409, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, objectTitle=Lancet Oncol：复发/难治性慢性淋巴细胞白血病采用维奈托克+依鲁替尼治疗的“开关”——最小残留病灶, objectType=article, longId=728635, objectId=9e8ce2863581, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e8ce2863581, replyNumber=0, likeNumber=119, createdTime=2022-09-18, rootId=0, userName=sunyl07, userId=1be8234, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e8ce2863581, moduleTitle=Lancet Oncol：复发/难治性慢性淋巴细胞白血病采用维奈托克+依鲁替尼治疗的“开关”——最小残留病灶, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e8ce2863581)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

淋巴细胞白血病

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#淋巴细胞白血病# #慢性淋巴细胞白血病#

淋巴细胞白血病全方位解析|从指南到实践，为医生提供全方位支持

2024-03-21发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

WHO 淋巴母细胞白血病/淋巴瘤分型 2016 版

2023-12-18发表于上海

sunyl07 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

J Clin Oncol：白消安 vs 全身放疗联合环磷酰胺治疗成人急性B淋巴细胞白血病

2023-04-10

sunyl07 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

Clin Cancer Res：维奈托克治疗前依鲁替尼导入治疗可有效改善慢性淋巴细胞白血病患者预后

2023-03-23

sunyl07 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

BCR-ABL1融合基因阳性急性淋巴细胞白血病的那些小秘密

2022-08-28

sunyl07 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

IJHS：美国急性淋巴细胞白血病的严重程度和死亡率住院：一项基于人群的研究

2023-04-26

sunyl07 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

Leuk Lymphoma：加拿大婴儿急性淋巴细胞白血病 (ALL)、亚二倍体 ALL 和混合表型急性白血病 (MPAL) 的预后因素和结局：来自 CYP-C 的报告

2023-04-08

sunyl07 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

ASCO 2022 | 慢性淋巴细胞白血病一线疗法：Calquence联合奥妥珠单抗持续生存获益：5年生存率达到90%！

2022-09-15

heli0118 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

Hematol Oncol：血清可溶性 CD23 水平是慢性淋巴细胞白血病首次治疗时间的独立预测因子

2023-02-22

sunyl07 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

Leukemia：纪春岩教授团队揭示急性T淋巴细胞白血病治疗新靶点

2023-08-02

sunyl07 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

药明巨诺宣布倍诺达®针对儿童及年轻成人复发或难治性B细胞急性淋巴细胞白血病的临床试验申请获批

2022-08-22

sunyl07 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

【即将直播】竺晓凡教授：儿童急性淋巴细胞白血病的诊治与并发症处理原则

2023-02-22

sunyl07 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

Lancet Haematol：Tisagenlecleucel在急性淋巴细胞白血病幼儿和婴儿患者中的临床真实数据

2023-08-19

sunyl07 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

一例颗粒性-急性T淋巴细胞白血病案例分享

2022-06-19

sunyl07 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

最强讲解|慢性淋巴细胞白血病诊断与鉴别诊断

2023-03-16

sunyl07 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

HAEMATOLOGICA：伊布替尼治疗不能诱导慢性淋巴细胞白血病的TP53克隆进化

2022-03-13

sunyl07 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

Int J Epidemiol：常见的遗传多态性会增加慢性淋巴细胞白血病和非黑色素瘤皮肤癌之间的联系

2022-07-27

sunyl07 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

HAEMATOLOGICA：接受阿卡拉布替尼单药治疗的慢性淋巴细胞白血病患者的心血管不良事件: 762例患者的汇总分析。

2022-05-16

sunyl07 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

NEJM Evid：固定疗程的伊布替尼联合维奈克拉（Ibr+Ven）一线治疗慢性淋巴细胞白血病结果公布（GLOW研究）

2023-02-17

sunyl07 (审核中...)

前往app查看评论内容

#淋巴细胞白血病#

Lancet Oncol：复发/难治性慢性淋巴细胞白血病采用维奈托克+依鲁替尼治疗的“开关”——最小残留病灶

2022-09-18

科室
- - 订阅+
  - 更多科室
工具
服务